These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 8115667)

  • 21. Simultaneous MAO-B and COMT inhibition in L-Dopa-treated patients with Parkinson's disease.
    Lyytinen J; Kaakkola S; Ahtila S; Tuomainen P; Teräväinen H
    Mov Disord; 1997 Jul; 12(4):497-505. PubMed ID: 9251066
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Selegiline (1-deprenyl) and low-dose levodopa treatment of Parkinson's disease. A double-blind crossover trial.
    Presthus J; Berstad J; Lien K
    Acta Neurol Scand; 1987 Sep; 76(3):200-3. PubMed ID: 3120487
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Selegiline as an adjunct to conventional levodopa therapy in Parkinson's disease. Experience with this type B monoamine oxidase inhibitor in 200 patients.
    Elizan TS; Yahr MD; Moros DA; Mendoza MR; Pang S; Bodian CA
    Arch Neurol; 1989 Dec; 46(12):1280-3. PubMed ID: 2511825
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An interim report of the effect of selegiline (L-deprenyl) on the progression of disability in early Parkinson's disease. The Parkinson Study Group.
    Shoulson I
    Eur Neurol; 1992; 32 Suppl 1():46-53. PubMed ID: 1425820
    [TBL] [Abstract][Full Text] [Related]  

  • 25. L-deprenyl in Alzheimer's disease. Preliminary evidence for behavioral change with monoamine oxidase B inhibition.
    Tariot PN; Cohen RM; Sunderland T; Newhouse PA; Yount D; Mellow AM; Weingartner H; Mueller EA; Murphy DL
    Arch Gen Psychiatry; 1987 May; 44(5):427-33. PubMed ID: 3107514
    [TBL] [Abstract][Full Text] [Related]  

  • 26. (-)Deprenyl in Parkinson's disease: a two-year study in the different evolutive stages.
    Giovannini P; Martignoni E; Piccolo I; Pacchetti C; Grassi MP; Nappi G; Caraceni T
    J Neural Transm Suppl; 1986; 22():235-46. PubMed ID: 3097258
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of MAO-b inhibitors in the treatment of Parkinson's disease.
    Ruggieri S; Stocchi F; Denaro A; Baronti F; Agnoli A
    J Neural Transm Suppl; 1986; 22():227-33. PubMed ID: 3097257
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effect of deprenyl washout in patients with long-standing Parkinson's disease.
    Djaldetti R; Ziv I; Melamed E
    J Neural Transm (Vienna); 2002 May; 109(5-6):797-803. PubMed ID: 12111469
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Deprenyl in the management of response fluctuations in patients with Parkinson's disease on levodopa.
    Schachter M; Marsden CD; Parkes JD; Jenner P; Testa B
    J Neurol Neurosurg Psychiatry; 1980 Nov; 43(11):1016-21. PubMed ID: 6777463
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Monoamine oxidase activity and monoamine metabolism in brains of parkinsonian patients treated with l-deprenyl.
    Riederer P; Youdim MB
    J Neurochem; 1986 May; 46(5):1359-65. PubMed ID: 2420928
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Selegiline and cognitive function in Parkinson's disease.
    Hietanen MH
    Acta Neurol Scand; 1991 Nov; 84(5):407-10. PubMed ID: 1776388
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Early combination of selegiline and low-dose levodopa as initial symptomatic therapy in Parkinson's disease. Experience in 26 patients receiving combined therapy for 26 months.
    Elizan TS; Moros DA; Yahr MD
    Arch Neurol; 1991 Jan; 48(1):31-4. PubMed ID: 1898848
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Selegiline (L-deprenyl) and L-dopa treatment of Parkinson's disease: a double-blind trial.
    Takahashi M; Yuasa R; Imai T; Tachibana H; Yorifuji S; Nakamura Y; Ogawa N
    Intern Med; 1994 Sep; 33(9):517-24. PubMed ID: 8000101
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effect of deprenyl (selegiline) on the natural history of Parkinson's disease.
    Tetrud JW; Langston JW
    Science; 1989 Aug; 245(4917):519-22. PubMed ID: 2502843
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Levodopa and deprenyl treatment effects on peripheral indices of oxidant stress in Parkinson's disease.
    Ahlskog JE; Uitti RJ; Low PA; Tyce GM; O'Brien JF; Nickander KK
    Neurology; 1996 Mar; 46(3):796-801. PubMed ID: 8618686
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety of selegiline (deprenyl) in the treatment of Parkinson's disease.
    Heinonen EH; Myllylä V
    Drug Saf; 1998 Jul; 19(1):11-22. PubMed ID: 9673855
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effect of deprenyl and levodopa on the progression of Parkinson's disease.
    Olanow CW; Hauser RA; Gauger L; Malapira T; Koller W; Hubble J; Bushenbark K; Lilienfeld D; Esterlitz J
    Ann Neurol; 1995 Nov; 38(5):771-7. PubMed ID: 7486869
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rationale for (-)deprenyl (selegiline) medication in Parkinson's disease and in prevention of age-related nigral changes.
    Knoll J
    Biomed Pharmacother; 1995; 49(4):187-95. PubMed ID: 7669938
    [TBL] [Abstract][Full Text] [Related]  

  • 39. (-)Deprenyl (Selegiline): past, present and future.
    Knoll J
    Neurobiology (Bp); 2000; 8(2):179-99. PubMed ID: 11061214
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Two weeks of treatment with deprenyl (selegiline) does not prolong L-dopa effect in parkinsonian patients: a double-blind cross-over placebo-controlled trial.
    Rascol O; Montastruc JL; Senard JM; Demonet JF; Simonetta M; Rascol A
    Neurology; 1988 Sep; 38(9):1387-91. PubMed ID: 3137488
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.